Breaking News

Lonza Expands Cell and Gene Therapy Portfolio

Launches new GMP-grade cytokines and AAV medium.

Author Image

By: Charlie Sternberg

Associate Editor

TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium.

Lonza Group AG has broadened its suite of cell and gene therapy manufacturing solutions with the launch of two new products: TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium. The additions are aimed at enhancing the scalability and consistency of advanced therapy production under Good Manufacturing Practice (GMP) conditions. The TheraPEAK AmpliCell Cytokines are designed to support immune cell expansion, activation, and differentiation. Manufactured using a mammalian expression syste...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters